Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT777101 in Hidradenitis Suppurativa
NCT06361836Phase 1Active, not recruiting
- Sponsor
- Sonoma Biotherapeutics
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of SBT777101 in hidradenitis suppurativa (HS) (3 arms), sponsored by Sonoma Biotherapeutics. Primary endpoints: Incidence, nature, and severity of adverse events and Dose Limiting Toxicities. Started Oct 2024; status: active, not recruiting.
02
Drugs
SBT777101
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06361836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361836.